RELMADA THERAPEUTICS, INC. Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross
RELMADA THERAPEUTICS, INC. (RLMD) reported Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross of $3.98 million for the 12-month period ending 2015-06-30, per its 10-K filed 2015-09-11.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross · last filed 2015-09-11
- RELMADA THERAPEUTICS, INC. research and development arrangement, contract to perform for others, costs incurred, gross for fiscal 2015 was $3.98M.
| Period end | Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross 12 month |
|---|---|
| 2015-06-30 | $3.98M 10-K · filed 2015-09-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |